Skip to main content
. Author manuscript; available in PMC: 2014 Sep 15.
Published in final edited form as: Clin Cancer Res. 2013 Jul 18;19(18):4917–4924. doi: 10.1158/1078-0432.CCR-12-1972

Table 1.

Combined Immune Checkpoint Blockade: Current Clinical Trials

Trial ID Target Disease Agents Description Phase
NCT01024231 Unresectable Stage III or IV Malignant Melanoma Nivolumab(BMS-936558)
Ipilimumab (BMS-734016)		 Phase I Dose Escalation Trial 1
NCT01472081 Metastatic
Renal Cell Carcinoma (Clear Cell)		 Nivolumab(BMS-936558)
Ipilimumab (BMS-734016)		 Experimental arms with Ipilimumab and Nivolumab at doses of 1 mg / kg + 3 mg / kg and 3 mg / kg + 1 mg/ kg respectively 1
NCT01454102 Non-small Cell Lung Cancer Nivolumab(BMS-936558)
Ipilimumab (BMS-734016)		 Various does combinations of Ipilimumab and Nivolumab 1
NCT01783938 Advanced or Metastatic Melanoma Nivolumab(BMS-936558)
Ipilimumab (BMS-734016)		 Randomized Phase II Study: Sequencing trial of Ipilimumab followed by Nivolumab verus Nivolumab followed by Ipilimumab 2
NCT01844505 Previously Untreated Unresectable or Metastatic Melanoma Nivolumab(BMS-936558)
Ipilimumab (BMS-734016)		 Randomized Phase III Trial of Ipilimumab, Nivolumab or Combination 3